DE69232946T2 - Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung - Google Patents
Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildungInfo
- Publication number
- DE69232946T2 DE69232946T2 DE69232946T DE69232946T DE69232946T2 DE 69232946 T2 DE69232946 T2 DE 69232946T2 DE 69232946 T DE69232946 T DE 69232946T DE 69232946 T DE69232946 T DE 69232946T DE 69232946 T2 DE69232946 T2 DE 69232946T2
- Authority
- DE
- Germany
- Prior art keywords
- methods
- cell regulatory
- decorin
- present
- regulatory factor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title abstract 7
- 208000032544 Cicatrix Diseases 0.000 title 1
- 230000009134 cell regulation Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 231100000241 scar Toxicity 0.000 title 1
- 230000037387 scars Effects 0.000 title 1
- 210000004027 cell Anatomy 0.000 abstract 6
- 102000004237 Decorin Human genes 0.000 abstract 5
- 108090000738 Decorin Proteins 0.000 abstract 5
- 102000004169 proteins and genes Human genes 0.000 abstract 4
- 230000001105 regulatory effect Effects 0.000 abstract 4
- 208000027418 Wounds and injury Diseases 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 206010052428 Wound Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000037983 regulatory factors Human genes 0.000 abstract 2
- 108091008025 regulatory factors Proteins 0.000 abstract 2
- 229920002683 Glycosaminoglycan Polymers 0.000 abstract 1
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002500 effect on skin Effects 0.000 abstract 1
- 108091006104 gene-regulatory proteins Proteins 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 210000004901 leucine-rich repeat Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000037390 scarring Effects 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/90—Fusion polypeptide containing a motif for post-translational modification
- C07K2319/91—Fusion polypeptide containing a motif for post-translational modification containing a motif for glycosylation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electroluminescent Light Sources (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79219291A | 1991-11-14 | 1991-11-14 | |
| US88234592A | 1992-05-13 | 1992-05-13 | |
| PCT/US1992/009871 WO1993009800A1 (en) | 1991-11-14 | 1992-11-13 | Inhibitors of cell regulatory factors and methods for preventing or reducing scarring |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69232946D1 DE69232946D1 (de) | 2003-04-10 |
| DE69232946T2 true DE69232946T2 (de) | 2003-12-18 |
Family
ID=27121246
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69232946T Expired - Fee Related DE69232946T2 (de) | 1991-11-14 | 1992-11-13 | Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP0667784B1 (de) |
| JP (1) | JPH07504886A (de) |
| AT (1) | ATE233568T1 (de) |
| AU (1) | AU673506B2 (de) |
| CA (1) | CA2123418A1 (de) |
| DE (1) | DE69232946T2 (de) |
| ES (1) | ES2188585T3 (de) |
| FI (1) | FI942244A (de) |
| NO (1) | NO941821L (de) |
| WO (1) | WO1993009800A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834444A (en) * | 1991-07-03 | 1998-11-10 | Hyal Pharmaceutical Corporation | Hyaluronic acid and salts thereof inhibit arterial restenosis |
| CA2157388C (en) * | 1993-03-01 | 1998-12-15 | Daniel P. Witt | Analogs for specific oligosaccharide-protein interactions and uses thereof |
| WO1995013827A1 (en) * | 1993-11-19 | 1995-05-26 | The University Of Sydney | A method for preventing or controlling cataract |
| GB2304045A (en) † | 1995-08-04 | 1997-03-12 | Univ Manchester | Betaglycan compositions for promoting the healing of wounds and fibrotic diseases |
| AU2008200019B2 (en) * | 1999-01-05 | 2009-10-08 | American National Red Cross | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| AU771635B2 (en) | 1999-01-05 | 2004-04-01 | American National Red Cross, The | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| WO2002068647A2 (en) * | 2001-01-16 | 2002-09-06 | Curagen Corporation | Proteins, polynucleotides encoding them and methods of using the same |
| CN1506042A (zh) | 2002-12-11 | 2004-06-23 | 苏加璐 | 使用来自胎儿细胞和组织的化合物改善皮肤状况的方法和组合物 |
| GB0309064D0 (en) | 2003-04-22 | 2003-05-28 | Univ Manchester | Modified peptides and their uses |
| EP2862867A3 (de) | 2005-10-25 | 2015-08-05 | The Johns Hopkins University | Verfahren und Zusammensetzungen zur Behandlung des Marfan-Syndroms und assoziierter Erkrankungen |
| EP1998810A4 (de) | 2006-03-13 | 2009-09-02 | Univ Johns Hopkins | Erhöhung der endothelialen thromboresistenz |
| PL2083863T3 (pl) | 2006-10-03 | 2015-08-31 | Genzyme Corp | Przeciwciała przeciwko TGF-beta do stosowania w leczeniu niemowląt obarczonych ryzykiem rozwinięcia się dysplazji oskrzelowo-płucnej |
| US10016452B2 (en) | 2008-05-01 | 2018-07-10 | The Regents Of The University Of California | Fibromodulin formulation for reducing corneal scarring |
| KR100983182B1 (ko) | 2009-08-14 | 2010-09-20 | (주)엔솔테크 | 신규 펩타이드 및 그 용도 |
| EP2660314A4 (de) | 2010-12-27 | 2014-09-03 | Lsip Llc | Ips-zellen und verfahren zu ihrer erzeugung |
| US20120238727A1 (en) * | 2011-03-14 | 2012-09-20 | Catalent Pharma Solutions Llc | Decorin compositions and use thereof |
| EP2737083A1 (de) | 2011-07-27 | 2014-06-04 | INSERM (Institut National de la Santé et de la Recherche Scientifique) | Verfahren zur diagnose und behandlung des myhre-syndroms |
| WO2013062544A1 (en) | 2011-10-26 | 2013-05-02 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| WO2013100208A1 (ja) | 2011-12-28 | 2013-07-04 | 京都府公立大学法人 | 角膜内皮細胞の培養正常化 |
| WO2014176198A1 (en) * | 2013-04-22 | 2014-10-30 | Catalent Pharma Solutions, Llc | Veterinary decorin compositions and use thereof |
| WO2015064768A1 (ja) | 2013-10-31 | 2015-05-07 | 京都府公立大学法人 | 角膜内皮の小胞体細胞死関連疾患治療薬 |
| WO2016187312A1 (en) | 2015-05-18 | 2016-11-24 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods and compositions for treating an alphavirus infection |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU633011B2 (en) * | 1988-06-28 | 1993-01-21 | La Jolla Cancer Research Foundation | Suppression of cell proliferation by decorin |
| ES2084688T3 (es) * | 1988-12-20 | 1996-05-16 | Jolla Cancer Res Found | Conjugados de polipeptido-polimero para el tratamiento de heridas. |
| WO1991010727A1 (en) * | 1990-01-22 | 1991-07-25 | La Jolla Cancer Research Foundation | Inhibitors of cell regulatory factors |
| GB9106678D0 (en) * | 1991-03-28 | 1991-05-15 | Ferguson Mark W J | Wound healing |
-
1992
- 1992-11-13 EP EP92925260A patent/EP0667784B1/de not_active Expired - Lifetime
- 1992-11-13 AT AT92925260T patent/ATE233568T1/de not_active IP Right Cessation
- 1992-11-13 EP EP02010251A patent/EP1230929A1/de not_active Withdrawn
- 1992-11-13 JP JP5509458A patent/JPH07504886A/ja active Pending
- 1992-11-13 AU AU31385/93A patent/AU673506B2/en not_active Ceased
- 1992-11-13 CA CA002123418A patent/CA2123418A1/en not_active Abandoned
- 1992-11-13 ES ES92925260T patent/ES2188585T3/es not_active Expired - Lifetime
- 1992-11-13 WO PCT/US1992/009871 patent/WO1993009800A1/en active IP Right Grant
- 1992-11-13 DE DE69232946T patent/DE69232946T2/de not_active Expired - Fee Related
-
1994
- 1994-05-13 FI FI942244A patent/FI942244A/fi not_active Application Discontinuation
- 1994-05-13 NO NO941821A patent/NO941821L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0667784A1 (de) | 1995-08-23 |
| ES2188585T3 (es) | 2003-07-01 |
| FI942244A (fi) | 1994-07-06 |
| AU673506B2 (en) | 1996-11-14 |
| DE69232946D1 (de) | 2003-04-10 |
| JPH07504886A (ja) | 1995-06-01 |
| EP1230929A1 (de) | 2002-08-14 |
| ATE233568T1 (de) | 2003-03-15 |
| CA2123418A1 (en) | 1993-05-27 |
| AU3138593A (en) | 1993-06-15 |
| NO941821D0 (no) | 1994-05-13 |
| NO941821L (no) | 1994-07-14 |
| WO1993009800A1 (en) | 1993-05-27 |
| FI942244A0 (fi) | 1994-05-13 |
| EP0667784B1 (de) | 2003-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69232946T2 (de) | Inhibitoren von zellregulationsfaktoren und verfahren zur verhütung oder verminderung von narbenbildung | |
| Lawrence et al. | The reversal of an Adriamycin induced healing impairment with chemoattractants and growth factors. | |
| Schuessler et al. | Oxygen effect in the radiolysis of proteins: Part 2 bovine serum albumin | |
| DE69730604D1 (de) | Oxadisäuren und verwandte verbindungen zur behandlung von hautstörungen | |
| DE69131847D1 (de) | Verwendung von kupfer enthaltenden wirkstoffen zur beschleunigung der wundheilung | |
| BG103594A (en) | Stable liquid interferon compositions | |
| DE69532996D1 (de) | Peptidanaloge des menschlichen basischen myelinproteins | |
| DE69331832D1 (de) | Diagnostische verfahren und pharmazeutische zusammensetzungen auf der basis von notch-proteinen und nukleinsäuren | |
| DE3879188D1 (de) | Verfahren zur vorbeugung und behandlung von mukositis mit granulozyt-kolonien stimulierendem faktor. | |
| DE69731385D1 (de) | Oxa-säuren und verwandte verbindungen zur behandlung von störungen der haut | |
| BR9507758A (pt) | Fração de copolímero-1 e composição para o tratamento de esclerose múltipla | |
| ATE300948T1 (de) | Verwendung von mangan-, yttrium- oder einigen lanthanidsalzen in einer kosmetischen, dermatologischen oder pharmazeutischen zusammensetzung insbesondere zur behandlung empflindlicher haut | |
| DE69233022D1 (de) | Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung | |
| ATE102949T1 (de) | Verfahren zur herstellung von retro-inversopeptiden und dessen zwischenprodukte. | |
| ATE66374T1 (de) | Zubereitungen und verfahren zur behandlung von blutungsstoerungen. | |
| ATE286974T1 (de) | Therapeutische domänen des von willebrand-faktor | |
| Vartio | Disulfide-bonded polymerization of plasma fibronectin in the presence of metal ions. | |
| ATE356145T1 (de) | Polypeptide zur regenerierung des nervensystems | |
| Ayad et al. | Type VI collagen and glycoprotein MFPI are distinct components of the extracellular matrix. | |
| EP0524737A3 (en) | Protein s. polypeptides and anti-peptide antibodies that inhibit protein s binding to c4b binding protein, diagnostic systems and therapeutic methods | |
| WO1997014966B1 (en) | Method of activating a novel ligand regulatory pathway | |
| US5514775A (en) | Chromogranin peptides | |
| KR100371976B1 (ko) | 혈장헤파린결합단백질-70 | |
| ATE329609T1 (de) | Peptide zur behandlung von wundkontraktion | |
| RU94023244A (ru) | Косметическая композиция для ухода за кожей |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |